Do analysts rate CRDL or ATHE?

Cardiol Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 687.04%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, CRDL or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is CRDL or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Alterity Therapeutics N/A N/A N/A

Do analysts rate SPRB or ATHE?

Spruce Biosciences presently has a consensus price target of $169.67, suggesting a potential upside of 246.05%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Spruce Biosciences is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, SPRB or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than Spruce Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spruce Biosciences $4.91M 27.46 -$38.97M -$36.60 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is SPRB or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -155.40% -101.67% Alterity Therapeutics N/A N/A N/A

Does the media favor SPRB or ATHE?

In the previous week, Spruce Biosciences had 5 more articles in the media than Alterity Therapeutics. MarketBeat recorded 8 mentions for Spruce Biosciences and 3 mentions for Alterity Therapeutics. Spruce Biosciences' average media sentiment score of 1.12 beat Alterity Therapeutics' score of 0.36 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ATHE or ACOG?

Alpha Cognition has a consensus price target of $14.67, suggesting a potential upside of 144.44%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger valuation and earnings, ATHE or ACOG?

Alterity Therapeutics has higher earnings, but lower revenue than Alpha Cognition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Alpha Cognition $10.22M 12.78 -$20.67M -$1.35 N/A

Does the media refer more to ATHE or ACOG?

In the previous week, Alterity Therapeutics had 1 more articles in the media than Alpha Cognition. MarketBeat recorded 3 mentions for Alterity Therapeutics and 2 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.89 beat Alterity Therapeutics' score of 0.36 indicating that Alpha Cognition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend ATHE or VTVT?

vTv Therapeutics has a consensus price target of $53.00, indicating a potential upside of 66.82%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 vTv Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has preferable earnings & valuation, ATHE or VTVT?

Alterity Therapeutics has higher earnings, but lower revenue than vTv Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A vTv Therapeutics $1.02M 122.72 -$26.97M -$0.93 N/A

Is ATHE or VTVT more profitable?

vTv Therapeutics' return on equity of 3.96% beat Alterity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A vTv Therapeutics N/A 3.96% 2.86%

Does the media prefer ATHE or VTVT?

In the previous week, Alterity Therapeutics had 1 more articles in the media than vTv Therapeutics. MarketBeat recorded 3 mentions for Alterity Therapeutics and 2 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.62 beat Alterity Therapeutics' score of 0.36 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ATHE or GNLX?

Genelux has a consensus price target of $18.00, suggesting a potential upside of 504.03%. Given Genelux's stronger consensus rating and higher probable upside, analysts clearly believe Genelux is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation and earnings, ATHE or GNLX?

Alterity Therapeutics has higher earnings, but lower revenue than Genelux. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Genelux $10K 13,362.32 -$32.15M -$0.85 N/A

Is ATHE or GNLX more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Genelux N/A -174.55% -123.65%

Does the media refer more to ATHE or GNLX?

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 3 articles in the media. Genelux's average media sentiment score of 0.43 beat Alterity Therapeutics' score of 0.36 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Alterity Therapeutics (ATHE) Competitors

$4.29 +0.37 (+9.44%)

Closing price 04:00 PM Eastern

Extended Trading

$4.30 +0.00 (+0.12%)

As of 07:46 PM Eastern

Compare

ATHE vs. CRDL, SPRB, ACOG, VTVT, and GNLX

Should you buy Alterity Therapeutics stock or one of its competitors? MarketBeat compares Alterity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alterity Therapeutics include Cardiol Therapeutics (CRDL), Spruce Biosciences (SPRB), Alpha Cognition (ACOG), vTv Therapeutics (VTVT), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry.

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alterity Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Alterity Therapeutics	N/A	N/A	N/A

Cardiol Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Cardiol Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 687.04%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

In the previous week, Alterity Therapeutics had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 3 mentions for Alterity Therapeutics and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.89 beat Alterity Therapeutics' score of 0.36 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardiol Therapeutics	Very Positive
Alterity Therapeutics	Neutral

Summary

Cardiol Therapeutics beats Alterity Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Alterity Therapeutics compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Alterity Therapeutics has lower revenue, but higher earnings than Spruce Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	27.46	-$38.97M	-$36.60	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Spruce Biosciences has a beta of 3.11, indicating that its share price is 211% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

Spruce Biosciences presently has a consensus price target of $169.67, suggesting a potential upside of 246.05%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Spruce Biosciences is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alterity Therapeutics' return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Alterity Therapeutics	N/A	N/A	N/A

In the previous week, Spruce Biosciences had 5 more articles in the media than Alterity Therapeutics. MarketBeat recorded 8 mentions for Spruce Biosciences and 3 mentions for Alterity Therapeutics. Spruce Biosciences' average media sentiment score of 1.12 beat Alterity Therapeutics' score of 0.36 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Spruce Biosciences beats Alterity Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Alterity Therapeutics compare to Alpha Cognition?

Alterity Therapeutics (NASDAQ:ATHE) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

2.1% of Alterity Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 14.0% of Alpha Cognition shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alterity Therapeutics has higher earnings, but lower revenue than Alpha Cognition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Alpha Cognition	$10.22M	12.78	-$20.67M	-$1.35	N/A

Alpha Cognition has a consensus price target of $14.67, suggesting a potential upside of 144.44%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Alterity Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Alterity Therapeutics' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Alpha Cognition	-232.23%	-58.35%	-45.99%

In the previous week, Alterity Therapeutics had 1 more articles in the media than Alpha Cognition. MarketBeat recorded 3 mentions for Alterity Therapeutics and 2 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.89 beat Alterity Therapeutics' score of 0.36 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alterity Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market.

Summary

Alterity Therapeutics beats Alpha Cognition on 7 of the 13 factors compared between the two stocks.

How does Alterity Therapeutics compare to vTv Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

In the previous week, Alterity Therapeutics had 1 more articles in the media than vTv Therapeutics. MarketBeat recorded 3 mentions for Alterity Therapeutics and 2 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.62 beat Alterity Therapeutics' score of 0.36 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alterity Therapeutics has higher earnings, but lower revenue than vTv Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
vTv Therapeutics	$1.02M	122.72	-$26.97M	-$0.93	N/A

Alterity Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

vTv Therapeutics has a consensus price target of $53.00, indicating a potential upside of 66.82%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

vTv Therapeutics' return on equity of 3.96% beat Alterity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
vTv Therapeutics	N/A	3.96%	2.86%

Summary

vTv Therapeutics beats Alterity Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Alterity Therapeutics compare to Genelux?

Alterity Therapeutics (NASDAQ:ATHE) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Alterity Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Genelux has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Alterity Therapeutics' return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Genelux	N/A	-174.55%	-123.65%

Genelux has a consensus price target of $18.00, suggesting a potential upside of 504.03%. Given Genelux's stronger consensus rating and higher probable upside, analysts clearly believe Genelux is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 3 articles in the media. Genelux's average media sentiment score of 0.43 beat Alterity Therapeutics' score of 0.36 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alterity Therapeutics has higher earnings, but lower revenue than Genelux.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Genelux	$10K	13,362.32	-$32.15M	-$0.85	N/A

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Genelux beats Alterity Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Alterity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHE vs. The Competition

Export

Metric	Alterity Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$34.76M	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	N/A	18.68	24.75	23.76
Price / Sales	N/A	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	1.38	8.06	10.47	6.72
Net Income	-$7.87M	$23.83M	$3.56B	$337.35M
7 Day Performance	6.88%	-2.82%	-1.11%	-2.54%
1 Month Performance	-7.94%	2.22%	1.28%	1.42%
1 Year Performance	-11.36%	37.70%	21.20%	24.71%

Alterity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHE Alterity Therapeutics	0.9144 of 5 stars	$4.29 +9.4%	N/A	-17.1%	$34.76M	N/A	N/A	10	News Coverage Gap Up High Trading Volume
CRDL Cardiol Therapeutics	2.6163 of 5 stars	$1.15 -5.7%	$8.50 +639.1%	-23.4%	$140.60M	N/A	N/A	20
SPRB Spruce Biosciences	3.0149 of 5 stars	$49.30 -2.8%	$176.60 +258.2%	+929.1%	$139.54M	$4.91M	N/A	20	News Coverage Positive News Analyst Forecast Gap Up
ACOG Alpha Cognition	4.3979 of 5 stars	$6.18 -2.5%	$14.67 +137.3%	-35.8%	$138.05M	$10.22M	N/A	N/A
VTVT vTv Therapeutics	2.8031 of 5 stars	$33.00 -3.8%	$53.00 +60.6%	+92.3%	$135.10M	$1.02M	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHE) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alterity Therapeutics (ATHE) Competitors

ATHE vs. CRDL, SPRB, ACOG, VTVT, and GNLX

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Summary

How does Alterity Therapeutics compare to Spruce Biosciences?

Summary

How does Alterity Therapeutics compare to Alpha Cognition?

Summary

How does Alterity Therapeutics compare to vTv Therapeutics?

Summary

How does Alterity Therapeutics compare to Genelux?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alterity Therapeutics (ATHE) Competitors

ATHE vs. CRDL, SPRB, ACOG, VTVT, and GNLX

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Do insiders and institutionals hold more shares of CRDL or ATHE?

Is CRDL or ATHE more profitable?

Which has more volatility and risk, CRDL or ATHE?

Do analysts rate CRDL or ATHE?

Which has better valuation and earnings, CRDL or ATHE?

Does the media favor CRDL or ATHE?

Summary

How does Alterity Therapeutics compare to Spruce Biosciences?

Which has higher earnings & valuation, SPRB or ATHE?

Do insiders & institutionals hold more shares of SPRB or ATHE?

Which has more risk & volatility, SPRB or ATHE?

Do analysts rate SPRB or ATHE?

Is SPRB or ATHE more profitable?

Does the media favor SPRB or ATHE?

Summary

How does Alterity Therapeutics compare to Alpha Cognition?

Do institutionals and insiders hold more shares of ATHE or ACOG?

Which has stronger valuation and earnings, ATHE or ACOG?

Do analysts prefer ATHE or ACOG?

Is ATHE or ACOG more profitable?

Does the media refer more to ATHE or ACOG?

Which has more volatility and risk, ATHE or ACOG?

Summary

How does Alterity Therapeutics compare to vTv Therapeutics?

Does the media prefer ATHE or VTVT?

Do insiders & institutionals believe in ATHE or VTVT?

Which has preferable earnings & valuation, ATHE or VTVT?

Which has more risk & volatility, ATHE or VTVT?

Do analysts recommend ATHE or VTVT?

Is ATHE or VTVT more profitable?

Summary

How does Alterity Therapeutics compare to Genelux?

Which has more volatility and risk, ATHE or GNLX?

Is ATHE or GNLX more profitable?

Do analysts prefer ATHE or GNLX?

Does the media refer more to ATHE or GNLX?

Which has preferable valuation and earnings, ATHE or GNLX?

Do insiders and institutionals hold more shares of ATHE or GNLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools